Hisamitsu Pharmaceutical Co Inc
Hisamitsu Pharmaceutical's GHG Emissions Data Preview
In 2022, Hisamitsu Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Hisamitsu Pharmaceutical has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2022 | 2021 | 2020 | 2019 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
aVerified Sources Behind Hisamitsu Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Hisamitsu Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Insights into Hisamitsu Pharmaceutical's Operational Emissions
In 2022, the total operational greenhouse gas (GHG) emissions of Hisamitsu Pharmaceutical amounted to 22,140 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2021, the total operational greenhouse gas (GHG) emissions of Hisamitsu Pharmaceutical decreased by 2.83%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a
Hisamitsu Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Hisamitsu Pharmaceutical's Scope 1 emissions?
In 2022, the total Scope 1 emissions of Hisamitsu Pharmaceutical were 7,862 metric tons of CO₂ equivalent (tCO₂e). a
Has Hisamitsu Pharmaceutical reduced its Scope 1 emissions over time?
Since 2018, Hisamitsu Pharmaceutical's Scope 1 emissions have decreased by 20.43%, reflecting a declining long-term trend in Scope 1 emissions over time. a
Compared to the previous year (2021), Hisamitsu Pharmaceutical's Scope 1 emissions increased by 13.56%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Hisamitsu Pharmaceutical's Scope 2 emissions?
In 2022, Hisamitsu Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 14,278 tCO₂e without specifying the calculation method. a
Has Hisamitsu Pharmaceutical reduced its Scope 2 emissions over time?
Since 2018, Hisamitsu Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have decreased by 13.96%, reflecting a declining long-term trend in Scope 2 emissions over time. a
Compared to the previous year (2021), Hisamitsu Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Hisamitsu Pharmaceutical 's emissions have plateaued with no significant change in its energy consumption footprint. a
What methodology does Hisamitsu Pharmaceutical use for Scope 2 reporting?
In 2022, Hisamitsu Pharmaceutical reported its Scope 2 emissions using an unspecified methodology. a
Hisamitsu Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Hisamitsu Pharmaceutical's Value Chain Emissions
In 2022, Hisamitsu Pharmaceutical reported 98,488 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2022 disclosure of Hisamitsu Pharmaceutical includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2021, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
Hisamitsu Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Hisamitsu Pharmaceutical's Scope 3 emissions?
In 2022, Hisamitsu Pharmaceutical reported total Scope 3 emissions of 98,488 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 72.77% of these emissions originated from upstream activities such as purchased goods and capital goods, while 27.23% came from downstream activities like product use, distribution, and end-of-life treatment. a
Has Hisamitsu Pharmaceutical reduced its Scope 3 emissions over time?
Since 2018, Hisamitsu Pharmaceutical's Scope 3 emissions have decreased by 11.64%, reflecting a declining long-term trend in Scope 3 emissions over time. a
Compared to the previous year (2021), Hisamitsu Pharmaceutical's Scope 3 emissions remained relatively stable, indicating that Hisamitsu Pharmaceutical 's emissions have plateaued with no significant change in its value chain footprint. a
What categories of Scope 3 emissions does Hisamitsu Pharmaceutical disclose?
In 2022, Hisamitsu Pharmaceutical reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Hisamitsu Pharmaceutical's Scope 3 emissions?
In 2022, the largest contributors to Hisamitsu Pharmaceutical's Scope 3 emissions were: a
- Purchased Goods and Services (Cat. 1): 49,823 tCO₂e (50.59%)
- End-of-Life Treatment of Sold Products (Cat. 12): 26,818 tCO₂e (27.23%)
- Capital Goods (Cat. 2): 11,651 tCO₂e (11.83%)
Hisamitsu Pharmaceutical's Scope 3 Emissions by Categories
Insights into Hisamitsu Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers
In 2022, Hisamitsu Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 7,862 tCO₂e and total revenues of USD 1,040 millions. This translates into an emissions intensity of 7.56 tCO₂e per millions USD. a
Hisamitsu Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers
How does Hisamitsu Pharmaceutical's GHG emissions intensity compare to its peers?
In 2022, Hisamitsu Pharmaceutical reported a Scope 1 emissions intensity of 7.56 tCO₂e per millions USD. Compared to the peer group median of 4.41 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a
Where does Hisamitsu Pharmaceutical rank on GHG emissions intensity within its industry?
In 2022, Hisamitsu Pharmaceutical ranked 18 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
Hisamitsu Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a
Insights into Hisamitsu Pharmaceutical's Total Carbon Footprint
In 2022, Hisamitsu Pharmaceutical reported a total carbon footprint of 120,628 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 3.45% increase compared to 2021, suggesting a rise in emissions across its operations or value chain. a
The largest contributor to Hisamitsu Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 81.65% of the company's total carbon footprint, followed by Scope 2 emissions at 11.84%. a